Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
UMR-CNRS 5510 Matéis, Université Claude Bernard Lyon 1, Villeurbanne, France.
Eye (Lond). 2024 Nov;38(16):3161-3168. doi: 10.1038/s41433-024-03256-1. Epub 2024 Jul 31.
To assess the prognostic value of subretinal (SRF) and intraretinal fluid (IRF) localizations in type 1 macular neovascularization (MNV) due to age-related macular degeneration (AMD).
Eyes were prospectively treated with anti-vascular epithelial growth factor (anti-VEGF) intravitreal injections (IVT) according to a Pro-Re-Nata (PRN) or Treat and Extend (TAE) regimen during 24 months. A total of 211 eyes with treatment-naïve type 1 MNV secondary to AMD were consecutively included. Eyes were divided between 2 groups according to the fluid localization: presence of SRF alone (SRF group), or presence of IRF associated or not with SRF (IRF ± SRF group).
At baseline the mean BCVA was 66.2 letters. SRF was present in 94.8% of eyes, IRF in 30.8%, and both in 25.6%. Data were available for 201 eyes at 12 months, and 157 eyes at 24 months. The presence of IRF at baseline was associated with lower baseline BCVA and significantly lower BCVA at 12 months (p < 0.001) and 24 months (p < 0.001). Eyes with SRF alone displayed better visual outcomes (BCVA at month 12, SRF = 74.3 letters, IRF ± SRF = 56.9 letters). In the presence of baseline IRF, fibrosis (p = 0.03) and atrophy (p < 0.001) were more frequently found at 24 months. In a multivariate model, the presence of baseline IRF was significantly associated with lower BCVA at month 12 but not at month 24.
In type 1 MNV, the presence of baseline IRF was associated with worse visual outcomes compared to SRF alone, and more frequent atrophy and fibrosis.
评估与年龄相关性黄斑变性（AMD）相关的 1 型黄斑新生血管（MNV）中视网膜下（SRF）和视网膜内（IRF）液定位的预后价值。
根据 Pro-Re-Nata（PRN）或治疗和扩展（TAE）方案，在 24 个月内对 211 只未经治疗的与 AMD 相关的 1 型 MNV 患眼进行了抗血管内皮生长因子（anti-VEGF）玻璃体内注射（IVT）的前瞻性治疗。这些患眼被分为两组：仅存在 SRF（SRF 组）或存在 IRF 伴或不伴 SRF（IRF±SRF 组）。
在基线时，平均 BCVA 为 66.2 个字母。94.8%的眼存在 SRF，30.8%的眼存在 IRF，25.6%的眼同时存在 SRF 和 IRF。在 12 个月时，有 201 只眼的数据可用，在 24 个月时，有 157 只眼的数据可用。基线时存在 IRF 与较低的基线 BCVA 相关，并且在 12 个月（p<0.001）和 24 个月（p<0.001）时 BCVA 显著较低。仅存在 SRF 的眼显示出更好的视力结果（第 12 个月的 BCVA，SRF=74.3 个字母，IRF±SRF=56.9 个字母）。在基线时存在 IRF 的情况下，24 个月时更频繁地发现纤维化（p=0.03）和萎缩（p<0.001）。在多变量模型中，基线时存在 IRF 与第 12 个月时的 BCVA 显著相关，但与第 24 个月时的 BCVA 无关。
在 1 型 MNV 中，与仅存在 SRF 相比，基线时存在 IRF 与较差的视力结果相关，并且更频繁地发生萎缩和纤维化。
